- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT07937982
Protocol CAUSE-05 RHINO (RHINO)
Respiratory Health & Infant Nasal 'Omics (RHINO) (CAUSE-05)
CAUSE-05/RHINO is an observational study designed to learn how babies' nasal cells grow and change during the first months of life. The study will enroll pregnant mothers in their third trimester and their infants upon delivery for a target population of 60 mother-baby pairs. Researchers will conduct up to 6 study visits and collect serial nasal samples through 4 months of age.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
This is an observational, multicenter study designed to assess developmental changes in in vivo and in cultured neonatal nasal epithelial cells. The study will enroll pregnant females in their third trimester of pregnancy as well as their infants upon delivery. Approximately 60 mother-infant pairs will be observed from birth to age 4 months to describe early-life developmental patterns of nasal cell gene expression, including genes related to type-II (T2) inflammation, immune response, and epithelial barrier function.
Studietype
Registrering (Antatt)
Kontakter og plasseringer
Studiekontakt
- Navn: James E Gern, MD
- Telefonnummer: 608-263-6201
- E-post: gern@medicine.wisc.edu
Studiesteder
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60611
- Ann & Robert H. Lurie Children's Hospital of Chicago
-
Hovedetterforsker:
- Rajesh Kumar, MD
-
Ta kontakt med:
- Sarah Godley
- Telefonnummer: 312-227-6454
- E-post: sgodley@luriechildrens.org
-
-
Missouri
-
St Louis, Missouri, Forente stater, 63110
- Washington University at St. Louis
-
Ta kontakt med:
- Gina Simpson
- Telefonnummer: 314-362-9139
- E-post: simpsong@wustl.edu
-
Hovedetterforsker:
- Katherine Rivera-Spoljaric, MD
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45229
- Cincinnati Children's Hospital Medical Center
-
Hovedetterforsker:
- Neeru Hershey, MD
-
Ta kontakt med:
- Molly Brausch-Bradner
- Telefonnummer: 513-803-0028
- E-post: molly.brausch-bradner@cchmc.org
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Prøvetakingsmetode
Studiepopulasjon
Pregnant maternal participants from the pre-selected recruitment census tracts designated by the CAUSE program, aged 18 years or older, with a gestational age greater than or equal to 28 weeks, in addition to one offspring of each maternal participant.
Beskrivelse
Inclusion Criteria:
-
Able to understand and provide informed consent
-
Age 18 years or older
-
Currently pregnant, with:
- Gestational age ≥ 28 weeks as confirmed by participant self-report
- Intent to deliver at a participating clinical site labor and delivery (L&D) center
-
Agrees to enroll infant into the study at birth
-
In the case of multiple gestation, agrees to enroll only one infant who will be randomly selected
-
Have a primary place of residence in one of the pre-selected recruitment census tracts as outlined in the Protocol CAUSE-05 (RHINO) Manual of Procedures (MOP) a. Participants who do not live in the pre-selected census tracts but live within the Office of Management and Budget (OMB) defined Metropolitan Statistical Area and have publicly funded health insurance will qualify for inclusion.
Exclusion Criteria:
- Inability or unwillingness to give written informed consent or comply with study protocol
- Insufficient proficiency in English or Spanish to provide informed consent and complete study procedures
- Obstetric complications present and/or anticipated that could, in the opinion of the investigator, impact the study objectives
- Pregnancy conceived via donor oocyte (egg donation)
- Known plans to move outside the pre-selected recruitment census tracts before the infant reaches 4 months of age
- Intent to transfer infant custody (e.g., via adoption or foster placement) within 4 months of birth
- Past or current medical problems that are not listed above, which, in the opinion of the investigator, may pose additional risks related to participation in the study, may interfere with the participant's ability to comply with the protocol, or may impact the interpretation of data obtained from the study.
Infants who meet any of the following criteria at the Birth Visit are not eligible for further study participation:
- Delivery before 36 weeks gestation
- Diagnosed at birth with any medical condition which, in the opinion of the investigator, may pose additional risks related to participation in the study, may interfere with the family's ability to comply with the protocol, or may impact the interpretation of data obtained from the study.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Observasjonsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og intervensjoner
Gruppe / Kohort |
|---|
|
Pregnant females 18 years and older and their infants upon delivery
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Gene expression of nasal swab RNA samples
Tidsramme: 4 months
|
Gene expression will be measured by whole transcriptome RNA sequencing |
4 months
|
Samarbeidspartnere og etterforskere
Etterforskere
- Studiestol: James E Gern, MD, University of Wisconsin, Madison
- Studiestol: Jo L Wilson, MD, University of Wisconsin, Madison
- Studieleder: Daniel Jackson, MD, University of Wisconsin, Madison
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- DAIT CAUSE-05
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Immunonology Database and Analysis Portal (ImmPort), a long-term archive of clinical and mechanistic data from DAIT-funded grants and contracts.
IPD-delingstidsramme
On average, within 24 months after database lock for the trial.
Tilgangskriterier for IPD-deling
Open access
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .